CVISION

Q1: What is the company name mentioned in the text?
A1: The company name mentioned in the text is CVISION.

Q2: What product or system developed by Diopsys allows for simple and fast electrophysiologic testing without discomfort or corneal risk for patients?
A2: The product or system developed by Diopsys is called Diopsys' pERG (pattern ERG) Vision Testing System, which uses highly conductive skin electrodes to perform electrophysiologic testing.

Q3: What type of glaucoma management can be achieved using Diopsys' pERG?
A3: Diopsys' pERG can help guide glaucoma management in a wide range of clinical situations, including verifying the level of IOP causing ganglion cell damage, determining if an occludable anterior chamber angle (PACS) requires treatment, and distinguishing normals from preperimetric glaucoma cases.

Q4: What is the main advantage of using Diopsys' pERG in glaucoma management?
A4: The main advantage of using Diopsys' pERG is that it allows for rapid detection of disease activity, saving time and chair time for clinicians to focus on patients who really need attention.

Q5: What type of retinal disease can be detected using Diopsys' full field flicker ERG?
A5: Diopsys' full field flicker ERG (ffERG) can detect diseased but still viable cells, allowing for intervention aiming for functional recovery and providing an objective assessment of cone and bipolar function over the entire retina.

Q6: What is the benefit of using ffERG in retinal disease management?
A6: The benefit of using ffERG is that it provides an objective measure of retinal function improvement after treatment, which can be easily and rapidly interpreted by clinicians.

Q7: Who is the distributor of Diopsys' NOVA Vision Testing System in Belgium?
A7: The distributor of Diopsys' NOVA Vision Testing System in Belgium is CVISION, and contact information can be obtained through email at sales@cvision.be.

Q8: What is the significance of transitioning from time domain to frequency domain in pERG analysis?
A8: Transitioning from time domain to frequency domain has transformed pERG into a clinically indispensable tool, allowing for early detection of RGC dysfunction and subsequent apoptosis, which precedes axonal loss.